1. Home
  2. LIXT vs SNOA Comparison

LIXT vs SNOA Comparison

Compare LIXT & SNOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LIXT
  • SNOA
  • Stock Information
  • Founded
  • LIXT 2005
  • SNOA 1999
  • Country
  • LIXT United States
  • SNOA United States
  • Employees
  • LIXT N/A
  • SNOA N/A
  • Industry
  • LIXT Biotechnology: Pharmaceutical Preparations
  • SNOA Biotechnology: Pharmaceutical Preparations
  • Sector
  • LIXT Health Care
  • SNOA Health Care
  • Exchange
  • LIXT Nasdaq
  • SNOA Nasdaq
  • Market Cap
  • LIXT 4.1M
  • SNOA 3.7M
  • IPO Year
  • LIXT N/A
  • SNOA 2007
  • Fundamental
  • Price
  • LIXT $1.93
  • SNOA $2.51
  • Analyst Decision
  • LIXT
  • SNOA
  • Analyst Count
  • LIXT 0
  • SNOA 0
  • Target Price
  • LIXT N/A
  • SNOA N/A
  • AVG Volume (30 Days)
  • LIXT 19.4K
  • SNOA 815.8K
  • Earning Date
  • LIXT 11-12-2024
  • SNOA 02-06-2025
  • Dividend Yield
  • LIXT N/A
  • SNOA N/A
  • EPS Growth
  • LIXT N/A
  • SNOA N/A
  • EPS
  • LIXT N/A
  • SNOA N/A
  • Revenue
  • LIXT N/A
  • SNOA $13,547,000.00
  • Revenue This Year
  • LIXT N/A
  • SNOA $23.89
  • Revenue Next Year
  • LIXT N/A
  • SNOA $25.45
  • P/E Ratio
  • LIXT N/A
  • SNOA N/A
  • Revenue Growth
  • LIXT N/A
  • SNOA 11.81
  • 52 Week Low
  • LIXT $1.31
  • SNOA $2.45
  • 52 Week High
  • LIXT $4.40
  • SNOA $9.40
  • Technical
  • Relative Strength Index (RSI)
  • LIXT 57.92
  • SNOA 41.74
  • Support Level
  • LIXT $1.85
  • SNOA $2.55
  • Resistance Level
  • LIXT $2.65
  • SNOA $3.25
  • Average True Range (ATR)
  • LIXT 0.18
  • SNOA 0.20
  • MACD
  • LIXT 0.03
  • SNOA -0.02
  • Stochastic Oscillator
  • LIXT 43.37
  • SNOA 16.25

About LIXT Lixte Biotechnology Holdings Inc.

Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

About SNOA Sonoma Pharmaceuticals Inc.

Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.

Share on Social Networks: